蛋白酶激活受体1 针对性查具有血静活性的潜在抗血栓性化合物从多角体Amplexicaule D. Don var. 这就是SinenseForb的意义
Shiyi Huang1, Xiangchang He1, Jie Dai1
1School of Pharmacy, Hunan University of Chinese Medicine, 300 Bachelors Road, Yuelu District, Changsha Hunan, 410208, China.
Cardiovascular drugs and therapy
|November 25, 2025
概括
这项研究确定了来自Polygonum amplexicaule的强有力的蛋白酶激活受体1 (PAR1) 抗体. 乙甲基酸和同源素显示出抗血栓作用,减少出血,提供新的治疗选择.
科学领域:
- 药理学和植物化学
- 血栓形成研究研究
- 自然产品 药物发现 药物发现
背景情况:
- 血栓形成具有重大健康风险,需要新的治疗策略.
- 目前的抗血栓治疗通常会带来出血并发症的风险.
- 多边形 (polygonum amplexicaule var.) 是一个多边形的多边形. sinense是生物活性化合物的潜在来源.
研究的目的:
- 选蛋白酶激活受体1 (PAR1) 抑制化合物来自Polygonum amplexicaule植物化学物质.
- 为了识别多途径抗血栓症的低出血副作用的活性成分.
- 为了达到抗血栓形成而不会破坏正常的血小板血静.
主要方法:
- 对接模拟和血小板聚合测试确定了PAR1-配体相互作用.
- 在体内血栓形成模型 (FeCl3诱导的CA和IVC结合) 评估了抗血栓疗效.
- 组织病理学分析,凝血和出血学测试评估了动物中的复合机制和出血副作用.
主要成果:
- 三种配体,包括表甲基酸盐,同源素和myricetin,表现出强烈的PAR1亲和力.
- 甲基甲酸和同源素表现出显著的抗血栓活性,降低了出血倾向.
- 这些化合物显示出作为有效的PAR1抗剂的前景.
结论:
- 一个综合性策略成功地确定了在血栓治疗中降低出血风险的天然化合物.
- 乙甲基酸和同源素是基于PAR1抗剂的抗血栓治疗的潜在候选者.
- 这项研究为药用植物的向治疗和机制探索提供了宝贵的见解.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K